eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2024
vol. 10
 
Share:
Send email
Share:
Original paper

Liver macrophage activation: Relation with hepatic histopathological changes in patients with metabolic associated steatotic liver disease

Doaa H. Hegazy
1
,
Fathalla S. Mohamed
2
,
Sabah A. H. Mahmoud
3
,
Nevine M. F. El Deeb
4
,
Amany S. Elyamany
2
,
Ahmed M. Elgendi
5

  1. Egypt Ministry of Health, Egypt
  2. Internal Medicine Department, Hepatology Unit, Faculty of Medicine, Alexandria University, Egypt
  3. Medical Biochemistry Department, Faculty of Medicine, Alexandria University, Egypt
  4. Pathology Department, Faculty of Medicine, Alexandria University, Egypt
  5. General Surgery Department, Hepatobiliary Surgery Unit, Faculty of Medicine, University of Alexandria, Egypt
Clin Exp HEPATOL 2024; 10, 2: 79-89
DOI: https://doi.org/10.5114/ceh.2024.139983
Online publish date: 2024/06/11
Article file
- Liver macrophage (1).pdf  [0.27 MB]
Get citation
 
PlumX metrics:
 
1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol 2023; 29: 101133.
2. Lekakis V, Papatheodoridis GV. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med 2024; 122: 3-10.
3. Ebrahimi F, Hagström H, Sun J, et al. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study. J Hepatol 2023; 79: 1374-1384.
4. Yanai H, Adachi H, Hakoshima M, et al. Metabolic-dysfunction-associated steatotic liver disease-its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments. Int J Mol Sci 2023; 24: 15473.
5. Parthasarathy G, Revelo X. Pathogenesis of nonalcoholic steatohepatitis: An overview. Hepatol Commun 2020; 4: 478-492.
6. Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci 2019; 76: 99-128.
7. Vonderlin J, Chavakis T, Sieweke M, Tacke F. The multifaceted roles of macrophages in NAFLD pathogenesis. Cell Mol Gastroenterol Hepatol 2023; 15: 1311-1324.
8. Svegliati-Baroni G, Pierantonelli I, Torquato P, et al. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease. Free Radic Biol Med 2019; 144: 293-309.
9. Cheng D, Chai J, Wang H, et al. Hepatic macrophages: Key players in the development and progression of liver fibrosis. Liver Int 2021; 41: 2279-2294.
10. Febbraio MA, Reibe S, Shalapour S, et al. Preclinical models for studying NASH-driven HCC: How useful are they? Cell Metab 2019; 29: 18-26.
11. Chen Y, Wang W, Morgan MP, et al. Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets. Front Endocrinol (Lausanne) 2023; 14: 1148934.
12. Velarde-Ruiz Velasco JA, García-Jiménez ES, García-Zermeño KR, et al. Extrahepatic complications of non-alcoholic fatty liver disease: Its impact beyond the liver. Rev Gastroenterol Mex (Engl Ed) 2019; 84: 472-481.
13. Gonzalez A, Huerta-Salgado C, Orozco-Aguilar J, et al. Role of oxidative stress in hepatic and extrahepatic dysfunctions during nonalcoholic fatty liver disease (NAFLD). Oxid Med Cell Longev 2020; 2020: 1617805.
14. Tomeno W, Imajo K, Takayanagi T, et al. Complications of non-alcoholic fatty liver disease in extrahepatic organs. Diagnostics (Basel) 2020; 10: 912.
15. Rosso C, Kazankov K, Younes R, et al. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. J Hepatol 2019; 71: 1012-1021.
16. Mueller JL, Feeney ER, Zheng H, et al. Circulating soluble CD163 is associated with steatohepatitis and advanced fibrosis in nonalcoholic fatty liver disease. Clin Transl Gastroenterol 2015; 6: e114.
17. Kanauchi M, Yamano S, Kanauchi K, Saito Y. Homeostasis model assessment of insulin resistance, quantitative insulin sensitivity check index, and oral glucose insulin sensitivity index in nonobese, nondiabetic subjects with high-normal blood pressure. J Clin Endocrinol Metab 2003; 88: 3444-3446.
18. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-36.
19. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E, et al. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008; 7: 350-357.
20. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854.
21. Ruffillo G, Fassio E, Alvarez E, et al. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol 2011; 54: 160-163.
22. Jude C, Dejica D, Samasca G, et al. Soluble CD163 serum levels are elevated and correlated with IL-12 and CXCL10 in patients with long-standing rheumatoid arthritis. Rheumatol Int 2013; 33: 1031-1037.
23. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
24. De Vito R, Alisi A, Masotti A, et al. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. Int J Mol Med 2012; 30: 49-56.
25. Kazankov K, Barrera F, Møller HJ, et al. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. Liver Int 2016; 36: 1549-1557.
26. Kazankov K, Jørgensen SMD, Thomsen KL, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2019; 16: 145-159.
27. Li H, Zhou Y, Wang H, et al. Crosstalk between liver macrophages and surrounding cells in nonalcoholic steatohepatitis. Front Immunol 2020; 11: 1169.
28. Hegazy MA, Mogawer SM, Alnaggar AR, et al. Serum LPS and CD163 biomarkers confirming the role of gut dysbiosis in overweight patients with NASH. Diabetes Metab Syndr Obes 2020; 13: 3861-3872.
29. Skytthe MK, Pedersen FB, Wernberg CW, et al. Obese patients with nonalcoholic fatty liver disease have an increase in soluble plasma CD163 and a concurrent decrease in hepatic expression of CD163. Gastro Hep Advances 2023; 2: 711-720.
30. Daemen S, Gainullina A, Kalugotla G, et al. Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH. Cell Rep 2021; 34: 108626.
31. Jin X, Qiu T, Li L, et al. Pathophysiology of obesity and its associated diseases. Acta Pharm Sin B 2023; 13: 2403-2424.
32. Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019; 92: 82-97.
33. Pal SC, Méndez-Sánchez N. Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis. World J Gastroenterol 2023; 29: 3999-4008.
34. Amor AJ, Perea V. Dyslipidemia in nonalcoholic fatty liver disease. Curr Opin Endocrinol Diabetes Obes 2019; 26: 103-108.
35. Schwenger KJP, Chen L, Chelliah A, et al. Markers of activated inflammatory cells are associated with disease severity and intestinal microbiota in adults with non alcoholic fatty liver disease. Int J Mol Med 2018; 42: 2229-2237.
36. Ma X, Liu S, Zhang J, et al. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol 2020; 20: 10.
37. Soresi M, Cabibi D, Giglio RV, et al. The prevalence of NAFLD and fibrosis in bariatric surgery patients and the reliability of noninvasive diagnostic methods. Biomed Res Int 2020; 2020: 5023157.
38. Önnerhag K, Hartman H, Nilsson PM, Lindgren S. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD). Scand J Gastroenterol 2019; 54: 328-334.
Copyright: © 2024 Clinical and Experimental Hepatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.